1. We will define the current standards for diagnosis and risk prediction in cancer therapy cardiotoxicity, with a specific
focus on doxorubicin and trastuzumab, sunitinib, and radiation therapy..
2. We will assess the role of imaging markers in risk prediction and diagnosis.
3. We will examine the role of biomarkers in risk prediction and diagnosis.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation